PMID- 36465634
OWN - NLM
STAT- MEDLINE
DCOM- 20221206
LR  - 20221213
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 13
DP  - 2022
TI  - The mechanism and efficacy of GLP-1 receptor agonists in the treatment of 
      Alzheimer's disease.
PG  - 1033479
LID - 10.3389/fendo.2022.1033479 [doi]
LID - 1033479
AB  - Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer's disease 
      (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs used 
      to treat T2DM have been gradually found to reduce the progression of AD in AD 
      models. Of these drugs, glucagon-like peptide 1 receptor (GLP-1R) agonists are 
      more effective and have fewer side effects. GLP-1R agonists have reducing 
      neuroinflammation and oxidative stress, neurotrophic effects, decreasing Abeta 
      deposition and tau hyperphosphorylation in AD models, which may be a potential 
      drug for the treatment of AD. However, this needs to be verified by further 
      clinical trials. This study aims to summarize the current information on the 
      mechanisms and effects of GLP-1R agonists in AD.
CI  - Copyright (c) 2022 Du, Meng, Yao and Xu.
FAU - Du, Haiyang
AU  - Du H
AD  - Division of Orthopedics, Department of Orthopedics, The Second Affiliated 
      Hospital of Harbin Medical University, Harbin, China.
FAU - Meng, Xiaoyu
AU  - Meng X
AD  - Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, 
      Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 
      China.
AD  - Branch of National Clinical Research Center for Metabolic Diseases, Hubei, China.
FAU - Yao, Yu
AU  - Yao Y
AD  - Division of Orthopedics, Department of Orthopedics, The Second Affiliated 
      Hospital of Harbin Medical University, Harbin, China.
FAU - Xu, Jun
AU  - Xu J
AD  - Division of Orthopedics, Department of Orthopedics, The Second Affiliated 
      Hospital of Harbin Medical University, Harbin, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20221117
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
SB  - IM
MH  - Humans
MH  - *Alzheimer Disease/drug therapy
MH  - Glucagon-Like Peptide-1 Receptor
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - *Drug-Related Side Effects and Adverse Reactions
MH  - *Insulin Resistance
PMC - PMC9714676
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - GLP-1R agonists
OT  - amyloid beta
OT  - cognitive function
OT  - tau phosphorylation
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/12/06 06:00
MHDA- 2022/12/07 06:00
PMCR- 2022/01/01
CRDT- 2022/12/05 03:46
PHST- 2022/08/31 00:00 [received]
PHST- 2022/10/27 00:00 [accepted]
PHST- 2022/12/05 03:46 [entrez]
PHST- 2022/12/06 06:00 [pubmed]
PHST- 2022/12/07 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2022.1033479 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2022 Nov 17;13:1033479. doi: 
      10.3389/fendo.2022.1033479. eCollection 2022.